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Summary
Background: Similarities between human inflammatory bowel disease (IBD) and ruminant para-
tuberculosis have fueled a heated discussion on the role of Mycobacterium avium subsp.
paratuberculosis (MAP) in the etiology of IBD.
Methods: In order to determine microbiological and immunological evidence of an association
between MAP and IBD, blood from 222 inflammatory bowel disease patients and 80 healthy donors
from the Basque Country (Spain) were subjected to nested PCR for MAP-specific insertion
sequence IS900, interferon-g (IFN-g) release test with PPA-3 MAP antigen (IFNMAP) or phos-
phate-buffered saline (IFNPBS), and antibody ELISA with PPA-3 MAP antigen (ABMAP).
Results: Highly significant differences in the proportion of PCR-positive IBD patients (17%) and
healthy controls (43%) as well as lower IFNMAP and higher ABMAP and IFNPBS responses were
observed. Treatment was associated with decreases in IFNMAP and PCR-positive frequency.
Conclusions: These results indicate the existence of immune responses and treatment interac-
tions with MAP that strongly support an etiological role of this agent in IBD.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +34 94 403 4300; fax: +34 94 403 4310.
E-mail address: rjuste@neiker.net (R.A. Juste).
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The term ‘inflammatory bowel disease’ (IBD) groups a set of
human illnesses that have in common a local chronic inflam-
mation of the intestine. Depending on the areas affected and
other clinical signs, three main types are recognized:
Crohn’s disease (CD), ulcerative colitis (UC), and indeter-
minate colitis (IDC). IBD etiology has not been established,
although themostwidely accepted hypothesis describes it as
a multifactorial disease where an anomalous immune
response induces a regional inflammation. The number of
cases of IBD is growing worldwide1,2 and the age of onset is
decreasing.3
Johne’s disease, a disease of the intestine of ruminants
caused by Mycobacterium avium subsp. paratuberculosis
(MAP), is also a local chronic inflammation. Due to similarities
between Johne’s disease and human IBD, MAP has also been
proposed as the causative agent of some cases of IBD,
especially CD.1,4—7 This connection between diseases was
first described by Dalziel in 19138 and subsequently by Crohn
and colleagues in 1932.9 However, attempts made since then
to substantiate an etiologic link between these diseases have
failed to change clinical practice.
Mortality from IBD is low, but the associated problems of
chronic illness, hospital admissions, drug toxicity, and sur-
gery present an important source of morbidity.10 The isola-
tion of MAP from the blood of 16 out of 37 IBD patients
tested,11 indicating bacteremia, has raised the not yet widely
accepted hypothesis of this infection being a zoonosis. Con-
sidering previous results on the presence of MAP DNA in the
blood of cattle and sheep,12 we aimed to confirm these
findings in a wider patient and control group setting and
to determine whether the detection of MAP DNA in blood is
associated with MAP-specific humoral and cellular immune
responses.
Materials and methods
Subject recruitment
Three hundred and two subjects were recruited from three
hospitals of the Basque Country in Northern Spain. Two
hundred and twenty-two were IBD patients: 63 patients from
the Quiro´n Donostia Clinic in Gipuzkoa, 59 patients from the
Hospital de Txagorritxu in Araba, and 100 patients from the
Hospital de Galdakao in Bizkaia. The diagnosis of IBD was
established on standard clinical endoscopic, histological, and
radiographic criteria by the patient’s physician. Treatment
and current status of the disease were confirmed via a
standard questionnaire that was completed by each patient
at the time of sampling with the help of a clinician. Most
patients were members of the local patient association,
Asociacio´n de Crohn y Colitis Ulcerosa (ACCU). Seventy-
one healthy blood donors used as a control cohort were
recruited from the Gipuzkoa Blood Bank, meeting all the
requirements for blood donation excluding major infections
and active disease but not putative asymptomatic disease.
Nine healthy laboratory workers were also included in the
control group. Informed consent was obtained from all sub-
jects according to the relevant national and European reg-
ulations.Blood sampling
Three 4-ml whole blood tubes were obtained from each
subject (two sterile EDTA vacutainer tubes (BD K3E) and
one lithium heparin vacutainer tube (LH); Plymouth, UK).
All blood samples were processed within 4 hours of collection
in a class II biosafety cabinet.
Nested PCR
Genomic DNAwas extracted from buffy coat cells from one of
the EDTA tubes with 155 mM ammonium chloride (1:1) for
20 min to lyse the red blood cells. The tube was then cen-
trifuged for 10 min at 200  g and the cell pellet was washed
twice with phosphate-buffered saline (PBS) by centrifugation
under the same conditions. The QIAamp DNA Blood Mini Kit
(Qiagen) was used to extract the DNA, which was stored at
20 8C until use. A nested PCR protocol for amplification of
insertion sequence IS900 was used according to Naser et al.11
To confirm the identity of the amplified products, the target
298-bp band from two positive controls and two IBD patients
was sequenced and verified by BLASTand sequence alignment
analysis.
Interferon (IFN)-g release ELISA test
Two 1.4-ml aliquots of blood were transferred to 1.5 ml vials.
To each tube, 100 ml of either 30 mg/ml MAP PPA-3 antigen
(Allied Monitor, Fayette, MO, USA) or PBS were added. All
tubes were incubated overnight at 37 8C. After incubation,
plasma was collected and stored at 20 8C until IFN-g levels
were measured with a commercial IFN-g ELISA assay (DuoSet
ELISA human IFN-g, R&D Systems, MN, USA). Upon plate
validation, PPA-3 (IFNMAP) and PBS (IFNPBS) absorbance
readings were used for statistical analysis.
MAP ELISA assay
Plasma samples were analyzed by an absorbed ELISA
using M. avium subsp. paratuberculosis PPA-3 antigen
(ABMAP) and an anti-human IgG1 horseradish peroxidase
conjugate. Assays were performed in duplicate as pre-
viously described.13 One bovine positive control serum
processed with its corresponding anti-bovine IgG was also
included in duplicate in each plate to control inter-plate
variability. Optical density was determined at 405 nm and
the average reading of both wells was divided by the
average reading of the positive control. Four samples were
not available for this analysis.
Statistical analysis
Comparisons of frequencies for overall IBD, IBD type, activity,
lesion location, and PCR result were made using the Fisher’s
exact test. IFN-g release and ELISA tests related to the same
qualitative variables mentioned above were analyzed by
different general linear model procedures after a logarithmic
transformation for IFN and without any transformation for
ABMAP. The natural logarithm transformation was chosen
among others to normalize for parametric testing of the
datasets that did not fully fit a normal distribution. Compar-
isons of means were carried out by Student’s t-test for
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‘any treatment’ versus ‘no treatment’. Statistical signifi-
cance was set at the p < 0.05-level. All statistical analyses
were made with the SAS statistical package (SAS Institute
Inc., Cary, NC, USA).
Results
Characteristics of patients and controls are summarized in
Table 1. Blood samples positive for the MAP-specific IS900
element showed a single bright 298-bp band (Figure 1) that
showed a 100% identity to the published IS900 sequence of
MAP when sequenced (data not shown). MAP DNA was
detected in 24% (72/302) of all blood samples distributed
as shown in Table 2. No significant differences were found
among IBD types, but the 2.5 times higher frequency of
positive results among controls than among IBD patients
was highly significant (Figure 2). No significant associations
were observed in relation to IBD type, lesion location, or
disease activity. If controls were included, the frequency ofTable 1 Characteristics of patients (N = 222) and controls (N = 8
CD
Number 124
Average age 38.8 (12.1)
Sex
Male 70 (56%)
Female 53 (43%)
ND 1 (1%)
Time from onset of disease 12.5 (0.8)
Activity
Active 21 (17%)
Inactive 99 (80%)
ND 4 (3%)
Medicationa
Mesalazine 72 (58%)
Azathioprine 30 (24%)
Sulfasalazine 1 (1%)
Mercaptopurine 2 (2%)
Methotrexate 2 (2%)
Prednisolone 14 (11%)
Budesonide 9 (7%)
Other 3 (2%)
No treatment 16 (13%)
Affected area
Colon 6 (5%)
Ileum 95 (77%)
Rectum 2 (2%)
Upper digestive tract 5 (4%)
ND 16 (13%)
In parentheses, standard deviation for means in years and percentage
ND, not determined; CD, Crohn’s disease; UC, ulcerative colitis; IDC,
laboratory workers.
a Several subjects were on more than one medication at the time ofPCR-positive results was significantly higher in the group
without treatment (Table 2).
The IFN-g and ELISA assay linear models had a moderate
explanatory value for the whole data variability (R2 below
0.20). However, controls showed a significantly higher
response to MAP antigen stimulation than the IBD group for
IFNMAP and lower for ABMAP and IFNPBS (Table 3) (Figure 2).
When blood PCR results were introduced in the model, the R2
values increased slightly, but no change in the pattern of
differences was observed. In particular, significant differ-
ences were observed for IBD patients versus controls in the
IFN-g assay when stimulated with MAP antigen, but not
between positive and negative PCR results globally. An inter-
action between disease group and PCR result was found for all
immune variables. The highest IFNMAP values were observed
in the PCR-positive group of control subjects, being higher
than the IBD group PCR-positive (F = 4.72; p = 0.03) (Table 3).
An interaction between disease group and PCR results was
also observed for ABMAP (F = 4.87; p = 0.03). This was due to
the significantly higher humoral response of the PCR-positive0)
UC IDC Control
90 8 80
44.2 (12.6) 51.1 (11.7) 39.2 (12.7)
48 (53%) 4 (50%) 35 (44%)
41 (46%) 4 (50%) 44 (55%)
1 (1%) - 1 (1%)
12.1 (1.0) 16.1 (3.1) -
16 (18%) 2 (25%) -
73 (81%) 6 (75%) -
1 (1%) - -
58 (64%) 6 (75%) -
16 (18%) - -
6 (7%) - -
1 (1%) - -
2 (2%) 1 (13%) -
10 (11%) 1 (13%) -
6 (7%) - -
3 (3%) - -
15 (17%) 2 (25%) -
46 (51%) 2 (25%) -
0 (0%) 1 (13%) -
32 (36%) 3 (38%) -
0 (0%) 0 (0%) -
12 (13%) 2 (25%) -
s for frequencies.
indeterminate colitis; control, healthy blood donors and healthy
study.
Table 2 PCR results according to type of disease, disease
activity, and affected area
Group
size (No.)
PCR-
positive
95% CI
All IBD, p < 0.0001
IBD 222 17% 12—22
Control 80 43% 32—54
Specific IBD type, NS ( p = 0.66)
CD 124 15% 9—21
UC 90 19% 11—27
IDC 8 25% 0—57
Activity, NS ( p = 0.11)
Active 39 26% 12—40
Inactive 178 16% 11—21
Affected area, NS (p = 0.20)
Colon 54 24% 13—35
Ileum 96 14% 7—21
Rectum 37 24% 10—38
Upper digestive tract 5 0% 0—60
Therapy, NS (p = 0.32)a; p < 0.0001b
Yesa, b 189 16% 11—21
No (controls not included)a 33 21% 7—35
No (only controls) b 80 43% 32—54
CI, confidence interval; IBD, inflammatory bowel disease; NS,
non-significant; CD, Crohn’s disease; UC, ulcerative colitis; IDC,
indeterminate colitis.
a Comparison of PCR-positive result frequencies between IBD
patients receiving any treatment and IBD patients not receiving
any treatment at the time of sampling.
b Comparison of PCR-positive result frequencies between IBD
patients receiving any treatment and healthy controls.
Figure 2 Humoral and cellular immune response. Relative
increment and p-values (in parentheses) of the IBD group over
the control group for mean absorbed antibody ELISA (ABMAP),
IFN-g in blood stimulated with MAP antigen (IFNMAP), or unsti-
mulated (IFNPBS) and frequency of PCR-positive individuals.
Positive values mean that the IBD group had higher means or
frequencies than the controls and negative ones that they were
lower.
Figure 1 Representative gels of nested PCR results of MAP-
specific IS900 DNA in blood samples. (A) Controls. (B) Patients. M,
molecular weight marker (1 Kb ladder; New England Biolabs,
Ipswich, MA, USA); lane 1, negative control of first round PCR;
lane 2, negative control of second round PCR; lanes 3—17 con-
trols (A) or IBD (B); lane 18, positive control DNA from MAP strain
ATCC 19698.
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and to the PCR-negative IBD group. The strongest interaction
was observed for IFNPBS (F = 6.01; p = 0.01) and was related
to the PCR-positive control group having the highest values,
as opposed to the IBD group where the PCR-negative indivi-
duals had the higher IFNPBS values (Table 3).
IBD type did not show any significant effect on IFNMAP,
IFNPBS, or ABMAP variables. Disease activity did not have any
significant effect on any immune response variables except
for the significantly higher ABMAP response of the inactive
and PCR-positive disease group compared with the inactive
and PCR-negative ( p = 0.004) and active and PCR-positive
( p = 0.03) groups.
Treatment appeared to be associated with an effect on all
the immune variables when the comparison was made
between IBD patients and controls, even though there were
also significant interactions with PCR results (Table 3). This
was a general effect on the IFNMAP response, which was
lowest in the IBD treated group versus both the IBD untreated
( p = 0.0475) and the control group ( p < 0.0001). If the PCR
results were taken into account, the PCR-positive IBD treated
group also had a lower IFNMAP mean than the untreated
( p = 0.0499) and than the controls ( p < 0.0001). A similar
pattern was observed when comparing the disease groups
within the PCR-negative group, where the IBD group yielded
lower IFNMAP values than the controls ( p < 0.0001). The
effect of treatment on the IFNPBS response was weaker and
statistically non-significant within the IBD group, although
this group had a lower response in the controls than in the IBD
patients when taken jointly ( p = 0.04)(Table 3). Treatment
also showed an effect on the antibody response (Table 3) with
an interaction ( p = 0.03) related to lack of differences
between PCR-positive and -negative groups among controls
( p = 0.26) and lower levels for the PCR-negative individuals
among treated patients ( p = 0.03). These effects followed
the same trend, but were never statistically significant when
only IBD patients untreated at the time of sampling were used
as the reference for comparison to IBD patients on treatment
(Table 3).
Table 3 Results of general linear models used to analyze IFN-g and ELISA data grouped according to disease type and PCR results,
and their interactions
All n PCR-positive n PCR-negative n
IFNMAP
IBD 0.185  0.034a 222 0.164  0.061a 38 0.206  0.028a, *NS ( p = 0.42) 184
Treated 0.171  0.038b 189 0.138  0.039b 31 0.203  0.017b, *NS (p = 0.40) 158
Untreated 0.248  0.046b 33 0.275  0.082b 7 0.221  0.043b, *NS (p = 0.07) 26
bp = 0.0475 bp = 0.0499 bNS (p = 0.61)
Control 0.661  0.043a 80 0.775  0.065a 34 0.547  0.056a, *p = 0.034 46
ap < 0.0001 ap < 0.0001 ap < 0.0001
Disease and PCR interaction, p = 0.03
Specific IBD type
CD 0.184  0.027 124 0.141  0.050 19 0.227  0.021, *NS (p = 0.12) 105
UC 0.188  0.051 90 0.198  0.053 17 0.177  0.026, *NS (p = 0.87) 73
IDC 0.128  0.089 8 0.087  0.155 2 0.169  0.089, *NS (p = 0.59) 6
IFNPBS
IBD 0.094  0.009a 222 0.077  0.016a 38 0.110  0.007a, *NS ( p = 0.06) 184
Treated 0.095  0.011b 189 0.079  0.020b 31 0.112  0.009b, *NS (p = 0.47) 158
Untreated 0.084  0.023b 33 0.069  0.042b 7 0.099  0.022b, *NS (p = 0.11) 26
bNS (p = 0.69) bNS (p = 0.82) bNS (p = 0.65)
Control 0.068  0.011a 80 0.083  0.017a 34 0.052  0.014a, *NS ( p = 0.17) 46
ap = 0.04 aNS ( p = 0.81) ap = 0.0001
Disease and PCR interaction, p = 0.01
Specific IBD type
CD 0.109  0.014 124 0.096  0.025 19 0.122  0.011, *NS (p = 0.34) 105
UC 0.076  0.015 90 0.058  0.027 17 0.095  0.013, *NS (p = 0.86) 73
IDC 0.071  0.045 8 0.064  0.077 2 0.078  0.045, *NS (p = 0.16) 6
ABMAP
IBD 0.615  0.023a 222 0.664  0.041a 38 0.567  0.019a, *p = 0.03 184
Treated 0.629  0.026b 189 0.687  0.048b 31 0.571  0.021b, *p = 0.03 158
Untreated 0.549  0.057b 33 0.560  0.100b 7 0.539  0.052b, *NS (p = 0.88) 26
bNS (p = 0.20) bNS (p = 0.25) bNS (p = 0.57)
Control 0.478  0.029a 80 0.445  0.044a 34 0.510  0.038a, *NS ( p = 0.26) 46
ap = 0.0002 ap = 0.0003 aNS ( p = 0.19)
Disease and PCR interaction, p = 0.03
Specific IBD type
CD 0.605  0.033 124 0.629  0.061 19 0.581  0.026, *NS (p = 0.47) 105
UC 0.624  0.036 90 0.700  0.065 17 0.547  0.031, *NS (p = 0.53) 73
IDC 0.617  0.109 8 0.685  0.189 2 0.549  0.109, *p = 0.03 6
Results are marginal mean  standard error of the mean.
IFNMAP: IFN-g ELISA optical density readings (OD) of MAP stimulated blood lymphocytes.
IFNPBS: IFN-g ELISA optical density readings of PBS (blank) stimulated blood lymphocytes.
ABMAP: MAP antigen (PPA-3) absorbed ELISA OD ratio to positive control OD readings.
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IDC, indeterminate colitis; control, healthy blood donors and
healthy laboratory workers; NS, non-significant ( p  0.05).
a,bStatistical significance of the difference between means with the same letter.
*Statistical significance of the difference between means of PCR-positive and PCR-negative groups in the same line.
All probabilities are calculated for logarithmically transformed IFN values and untransformed ELISA. Displayed means and standard errors
are untransformed in order to present an estimate of standard error that is meaningful in relationship to the mean and not affected by the
transformation.
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Table 4 Comparison between anti-MAP antibodies and
blood PCR-positive results in humans (current study), cattle,
and sheep.12 Notice that human values fall within the range of
sheep and cattle for all combinations
ELISA-positive ELISA-negative
PCR-pos PCR-neg PCR-pos PCR-neg
Humans (n = 302) * 2.3% 8.9% 21.5% 67.2%
Cattle (n = 184) 2.2% 38.0% 23.9% 35.9%
Sheep (n = 180) 3.3% 6.7% 8.9% 81.1%
* ELISA cut-off: 0.885.
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The most unexpected finding of this study was the higher
frequency of MAP DNA-positive results in the healthy control
group. This observation clearly opposes a conventional para-
digm on etiology of infectious diseases where an agent is
more frequently associated with diseased individuals than
with healthy ones. Since IBD is a disease that has challenged
the biomedical community for nearly a century, a conven-
tional pathogeneticmechanism cannot be expected. In fact,
a causal relationship in the onset of IBD with an unregulated
response to an infectious pathogen has been highly contro-
versial and has generated a number of potential candidates.
Following previous inconclusive studies, Naser et al.11
demonstrated a significant association between MAP bac-
teremia and CD. Our data roughly confirm the finding of MAP
in the blood of IBD patients, but show that the presence of
the IS900 sequence is even more widespread in healthy
subjects. These discrepancies between studies can be
explained by the number of samples and types of control
used in both studies.
There is recent new evidence on the relationship of MAP
and IBD pointing to an association between immune
mechanisms and MAP,6 that current IBD treatments actually
have an antibiotic effect on MAP,14—16 and one inconclusive
trial that is interpreted by the authors as suggesting anti-
biotics aimed at the M. avium group do not cure IBD.17 Even
more recently, a decreased frequency of MAP DNA-positive
results in the blood of IBD patients was associated to certain
IBD treatments.18
The work of Clancy et al.6 showed the involvement of MAP
and tumor necrosis factor-a (TNF-a) at the tissue level. That
study’s concept resembles ours in the sense that both try to
demonstrate an association between MAP and an immune
response to it in IBD. Methodological differences, however,
make it difficult to compare the specific results of these
studies, although some of the similarities that can be found
are similar proportions of PCR-positive results among IBD
patients and controls, pointing to a widespread presence
of MAP DNA in the general population. These authors also
found higher TNF-a production among IBD patients versus
controls, thus suggesting a possible failure of MAP-positive
IBD patients to elicit a normal immune response that can
clear the infection.
In the present study, the higher IFNMAP levels in controls
as compared to IBD patients are consistent with a higher rate
of PCR-positive results in controls indicating that healthy
individuals (but not IBD patients) raise a significant specific
cellular immune response correlated with the presence of
the suspect agent. This epidemiologic situation mimics that
of ruminant paratuberculosis in the sense that many animals
are infected, but only a few develop the disease,19 and that
ELISA and PCR-positive proportions fall within the range of
cattle and sheep values (Table 4). Likewise, in humans with
tuberculosis or helicobacteriosis only a few of the infected
individuals develop clinical symptoms.20,21 If high infection
prevalence and IFNMAP responses among the healthy popu-
lation can mostly be explained as subclinical forms of infec-
tion, the combination of lower DNAemia and lower IFNMAP
levels in IBD patients could be related to paratuberculosis
where it is not so uncommon to find erratic IFNMAP results,
no antibody responses, and difficult agent isolation.22 Apossible explanation of these phenomena could be an inter-
action with the drugs that most of the patients in this study
were taking at the time of sampling, which would cause a
direct effect on the immune-mediated inflammatory
responses as well as an indirect one caused by a lower
frequency of circulatingMAP.15 Still, the IBD patients showed
an increased antibody response that could be related to a
larger or longer availability of antigens and this can be seen
in other slow infections like paratuberculosis, where anti-
body responses are of low protective value and usually occur
only when the infection is well established and has a pro-
gressive course.
The results regarding increased IFNPBS levels associated
with IBD, which is the second most striking finding in our
study and has never been studied with regard to IBD, needs a
new pathogenetic model involving IFN-g receptor blocking.
The simplest explanation is that like Mycobacterium avium
subsp. avium,3,23 MAP can cause a reduced expression of IFN-
g receptors in the infected macrophage cells so that it
cannot be properly metabolized. A more complex explana-
tion is that a genetic deficiency, like that occurring in the
rare condition called Mendelian susceptibility to mycobac-
teria, where affected individuals have raised levels of IFN-g
due to lack of function of the IFN-g receptors (IFNGR1,
IFNGR2),24 is involved. Although IBD obviously is not a Men-
delian type genetic disease, and other genetic factors
related to intracellular bacterial infections have been
demonstrated in the etiology of IBD (i.e., NOD2,25,26
TLR4, CD14,26 and more recently ATG16L1),27 partial block-
ing of IFN-g receptors might explain both increased IFNPBS
levels and the lack of an efficient specific adaptive immune
response.28 In this scenario, a blocked innate immune
response can persist locally at the points of entrance of
MAP in the intestine. MAP fits with the feature of low
virulence that characterizes the bacteria involved in Men-
delian susceptibility, but perhaps as a result of its long
generation time it might be more easily contained in the
intestinal mucosa and associated lymphoid tissues than
other pathogens.
Our results showed a strong epidemiological association
between MAP in blood and specific and non-specific immune
responses. Since the type of association observed is unex-
pected because of its negative character regarding the
cellular immune response and positive character related
to the humoral immune response, it does not fit with con-
ventional infectious disease models. For this reason, we
propose an IBD model in which MAP, a low virulence myco-
bacterium, infects a large part of the human population
Figure 3 Proposed model for the etiology of IBD in relation to antibody and IFN-g responses and MAP presence. IFNPBS, IFNMAP, and
ABMAP values are group means.
Mycobacterium avium subsp. paratuberculosis in IBD 253but only causes a regional disease in a small part of it. This
susceptibility could be related to genetic factors associated
with a dysfunctional IFN-g activity that would fail to prop-
erly modulate the transition between innate and adaptive
immune response or to innate immune response type local
pathogenetic mechanisms triggered by the agent (Figure 3).
The lack of association with type of IBD or activity, though
limited by the cross-sectional nature of our study, supports
the view that they are different manifestations of the same
disease, which could be defined as a typical type II myco-
bacterial infection29 on the tuberculoid end of the immu-
nopathological spectrum. This model is also likely to be
valid for animal IBD where the lesions are more restricted to
the intestine and associated lymphoid tissue, but where a
larger spectrum of histological lesions can be seen. An
important corollary to this hypothesis is that adaptive
specific immune responses might not be so relevant in
the pathogenesis of human and animal IBD. This fact
explains the difficulties in ascribing an etiological role of
MAP in human IBD, as well as indicating that a new weight
must be given to classical pathological methods that can
characterize the morphological changes triggered by local
innate immune responses, like the case of infections of
accepted mycobacterial etiology.30,31 Clearly any further
work to validate this hypothesis must take into account that
case studies cannot be limited solely to a clinical case
definition and that naturally acquired paratuberculosis in
animals represents the closest available model for infec-
tious IBD in humans. It should not be overlooked that
proving this hypothesis might open the way to efficient
antibiotic and immune therapies that could dramatically
improve IBD patient health and quality of life, as well as
allow the design of new strategies for the control of rumi-
nant paratuberculosis.Acknowledgements
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